Pharmaceuticals, Biotechnology and Life Sciences
CARB-X is partnering with Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity…
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.